Kepler Capital Maintains Hold Rating on Cegedim with €14.00 Price Target

Cegedim, a company in the Technology sector, received a Hold rating from Hugo Paternoster of Kepler Capital with a price target of €14.00. The company's shares closed at €10.50 last Friday. Paternoster has an average return of 7.7% and a 57.35% success rate on recommended stocks. Another analyst, TR | OpenAI – 4o, also reiterated a Hold rating with a €10.50 price target.

Pharvaris B.V. (NASDAQ: PHVS) continues to attract analyst attention as it awaits pivotal data from its HAE therapy. BofA Securities has reiterated its Underperform rating and $14.00 price target on the stock, currently trading at $18.68 [1]. The investment bank expects topline data from the RAPIDe-3 pivotal phase 3 study in the fourth quarter of 2025, with a potential NDA submission in the first half of 2026 if the data is positive.

Analysts’ price targets range from $14.73 to $56.46, with four analysts recently revising their earnings estimates upward. Pharvaris holds more cash than debt, with a strong current ratio of 11.1, but is rapidly burning through its cash reserves. BofA Securities models peak penetration for deucrictibant at 20% of the addressable market, noting Kalvista’s Ekterly has a 12-month market exclusivity period before Pharvaris could potentially enter the market.

Citizens JMP analysts have reiterated their Market Outperform rating for Pharvaris, maintaining a price target of $55. They anticipate Phase 3 data for deucrictibant in 2026, with potential U.S. launches in 2027 for acute treatment and 2028 for prophylactic use, projecting peak sales of $600 million and $1.6 billion, respectively [2].

Pharvaris has presented data at the European Academy of Allergy and Clinical Immunology Congress 2025, showing sustained attack reduction and quality of life improvements in the CHAPTER-1 study, and early symptom relief in the RAPIDe-2 study. The company is conducting Phase 3 studies, CHAPTER-3 and RAPIDe-3, to evaluate the drug’s efficacy for prevention and on-demand treatment, respectively.

Cegedim, a Technology sector company, received a Hold rating from Hugo Paternoster of Kepler Capital with a price target of €14.00. The company's shares closed at €10.50 last Friday. Paternoster has an average return of 7.7% and a 57.35% success rate on recommended stocks. Another analyst, TR | OpenAI – 4o, also reiterated a Hold rating with a €10.50 price target [3].

References:
[1] https://in.investing.com/news/analyst-ratings/pharvaris-stock-awaits-pivotal-hae-therapy-data-as-bofa-reiterates-underperform-93CH-4907584
[2] https://in.investing.com/news/analyst-ratings/pharvaris-stock-awaits-pivotal-hae-therapy-data-as-bofa-reiterates-underperform-93CH-4907584
[3] https://in.investing.com/news/analyst-ratings/pharvaris-stock-awaits-pivotal-hae-therapy-data-as-bofa-reiterates-underperform-93CH-4907584